Other News To Note

• Immune Pharmaceuticals Ltd., of Herzliya-Pituach, Israel, and EpiCept Corp., of Tarrytown, N.Y., said Immune is initiating a Phase II double-blind placebo-controlled study with its lead drug bertilimumab in patients with moderate-to-severe ulcerative colitis.